Physician profile
John Sr C Maize
NPI 1982683611
$1,381.94
in general payments reported to CMS, 2019-2025
13 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $881 · 2022: $34.68 · 2023: $27.86 · 2024: $83.55 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurobindo Pharma USA, INC. | $700.00 | 2020 | |
| Amgen INC. | $121.98 | 2019-2023 | Otezla, Enbrel |
| Sun Pharmaceutical Industries INC. | $113.29 | 2019-2020 | |
| Pfizer INC. | $92.85 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $72.73 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $70.60 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $67.32 | 2025 | Zoryve |
| Organogenesis INC. | $57.56 | 2024 | |
| Incyte Corporation | $25.99 | 2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $20.88 | 2025 | Dupixent |
| Janssen Biotech, INC. | $16.58 | 2025 | Tremfya |
| Genentech USA, INC. | $16.23 | 2019 | |
| Prugen, INC. Pharmaceuticals | $5.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sr Maize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.